MRI findings of radiation-associated @entity5425 ( XXXX ).

@entity1 @entity5425 @entity0
PURPOSE: To describe the magnetic resonance imaging (MRI) characteristics of @entity5425 ( @entity5425 ). MATERIALS AND METHODS: In this Institutional Review board (IRB)-approved retrospective study, 57 @entity1 were diagnosed with pathologically confirmed @entity5425 during the study period (January 1999 to May 2013). Seventeen @entity1 underwent pretreatment breast MRI (prior to surgical resection or chemotherapy), of which 16 studies were available for review. Imaging features, including all available mammograms, ultrasounds, and breast MRIs, of these @entity1 were evaluated by two radiologists independently and correlated with clinical management and outcomes. RESULTS: The median age of @entity1 at original @entity0 was 69.3 years (range 42-84 years), with average time from initial radiation therapy to diagnosis of @entity5425 of 7.3 years (range 5.1-9.5 years). Nine @entity1 had mammograms (9/16, 56%) and six had breast ultrasound (US) (6/16, 38%) prior to MRI, which demonstrated nonsuspicious findings in 5/9 mammograms and 3/6 ultrasounds. Four @entity1 had distinct intraparenchymal masses on mammogram and MRI. MRI findings included diffuse T2 high signal skin thickening (16/16, 100%). Nearly half (7/16, 44%) of @entity1 had T2 low signal intensity lesions; all lesions rapidly enhanced on postcontrast T1 -weighted imaging. All @entity1 underwent surgical resection, with 8/16 (50%) receiving neoadjuvant chemotherapy. Four @entity1 died during the study period. CONCLUSION: Clinical, mammographic, and sonographic findings of @entity5425 are nonspecific and may be occult on conventional breast imaging; MRI findings of @entity5425 include rapidly enhancing dermal and intraparenchymal lesions, some of which are low signal on T2 weighted imaging. J. Magn. Reson. Imaging 2014.
